High materiality8/10
RBC Capital on Cytokinetics (CYTK): 'The stock is significantly undervalued despite today's move'
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
RBC Capital updated CYTK with a bullish target; target is $119 vs a posted price of $75.21. Price has moved +2.26% since the signal.
Key facts
- 01
Target: $119
- 02
Posted price: $75.21
- 03
Analyst firm: RBC Capital
- 04
Analyst: Leonid Timashev
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.